Biotech companies at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
34 biotech companies are at TIDES Europe 2026 — 40 presentations on the program and 2 with a booth in the exhibit hall. Most represented: Alnylam Pharmaceuticals (2 on the program), Constructive Bio (2 on the program), Ionis Pharmaceuticals (2 on the program). 9 of them have their own page in this guide. As of Sep 25, 2026.
Focus
Top represented
Showing 1–17 of 34 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Alnylam Pharmaceuticals Cambridge, MA | |
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases. | Talk Thu Nov 5 15:00–15:30 Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them. Talk Thu Nov 5 10:45–11:25 Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies. |
CB Constructive Bio Cambridge, United Kingdom | |
Develops genetic code expansion technology to make proteins and peptides containing non-standard amino acids. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 13:30–13:45 |
Ionis Pharmaceuticals Carlsbad, CA | |
Develops and markets antisense oligonucleotide medicines for neurological, cardiometabolic and rare diseases. | Talk Wed Nov 4 08:35–09:05 Regulatory CMC Strategies and Health Authority Interactions for Oligonucleotide Programs How manufacturing and quality filings for antisense drugs differ between the US and other regions, drawn from recent commercial applications. Talk Thu Nov 5 08:35–09:05 Moving Towards a Greener SPOS Process Practical ways to cut the environmental cost of oligonucleotide synthesis, including smaller wash volumes, new column designs and recycled solvent. |
Wave Life Sciences Cambridge, Massachusetts | |
Develops stereopure oligonucleotide medicines, including siRNA, antisense and RNA editing candidates. | Talk Wed Nov 4 09:05–09:35 Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA Designing siRNA the way chemists design small-molecule drugs, controlling each linkage to get lasting gene silencing in mouse liver and kidney. Talk Thu Nov 5 16:30–17:00 Synthesis and Characterization of Stereopure Chimeric Oligonucleotides Making and testing oligonucleotides in which every backbone link has one fixed mirror-image form, in small batches, to link structure to activity. |
Zealand Pharma Søborg, Denmark | |
Danish biotech developing peptide medicines for obesity and metabolic diseases, including amylin and GLP-1 analogues. | Talk Wed Nov 4 16:15–16:45 Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%. Talk Fri Nov 6 10:30–10:55 |
Develops oral treatments for obesity and metabolic disease, including a beaded glucose formulation that activates enteroendocrine cells. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. |
Silence Therapeutics London, United Kingdom | |
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases. | Talk Wed Nov 4 10:15–10:45 Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages. |
OmniAb Emeryville, California | |
Licenses antibody discovery platforms built on transgenic animals to drug developers. | Booth Exhibiting (no floor booth listed) Wed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm Talk Wed Nov 4 09:55–10:05 OmniUltra™: A Dual Modality In Vivo Discovery Platform for Novel Human Antibodies and Structured Peptides How antibodies carrying unusually long loops can reach deep pockets on a target, and how those loops work alone as small peptides. PeptidesDiscovery & Clinical |
A Affilogic Nantes, France | |
Develops Nanofitins, small engineered protein scaffolds used as targeting ligands and therapeutics, including for organ-specific oligonucleotide delivery. | Talk Thu Nov 5 08:05–08:35 Organ Specific Delivery of Oligonucleotides Using Nanofitins How small engineered proteins attached to siRNA carried it into brain and heart muscle in animals and switched off a target gene. |
A AIRNA Cambridge, MA | |
Develops RNA editing medicines, including a GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency. | Talk Wed Nov 4 10:45–11:15 AIR-001: A Highly Potent and Precise GalNAc-conjugated RNA Base Editing Treatment for Alpha-1 Antitrypsin Deficiency Animal results and first-trial progress for an oligonucleotide that corrects the mutation causing alpha-1 antitrypsin deficiency, which damages lung and liver. |
AT Altamira Therapeutics | |
Develops xPhore and related peptide-based platforms for delivering therapeutic nucleic acids such as siRNA and mRNA. | Talk Thu Nov 5 11:15–11:45 xPhore: A Platform for DeLivering Therapeutic Nucleic Acids A peptide that wraps around nucleic acid cargo to form nanoparticles aimed at tumours and inflamed tissue rather than the liver. |
Develops the synthetic antimicrobial peptidomimetic voxvoganan as an active ingredient for antimicrobial medical device coatings. | Talk Thu Nov 5 14:00–14:30 Voxvoganan - A First in Class Mimetic of Antimicrobial Peptides A three-amino-acid mimic of natural antibacterial peptides, how it was designed, and how it is made at industrial scale. |
AT Arrakis Therapeutics | |
Develops medicines that target RNA. | Talk Wed Nov 4 11:15–11:45 AIC468, A First-in-class Antisense Oligonucleotide Targeting BKV in Kidney Transplant Patients Animal and early trial safety data on an antisense drug against a virus that can destroy a transplanted kidney. |
Avidity Biosciences San Diego, CA | |
Develops antibody oligonucleotide conjugates (AOCs) that deliver RNA therapeutics to muscle for neuromuscular diseases. | Panel Thu Nov 5 10:15–10:45 From Small-Scale Knowledge to Commercial-Scale Manufacturing: Using Control Strategy to Justify Scale-up How proving which process settings truly matter lets a small-scale recipe justify making the same oligonucleotide at commercial scale. |
Bicycle Therapeutics Cambridge, United Kingdom | |
Develops bicyclic peptide therapeutics, including toxin and radionuclide conjugates, for cancer and other diseases. | Talk Thu Nov 5 14:30–15:00 Bicyclic Peptide Technology: Pioneering Next-Generation Precision-Guided Therapeutics How small looped peptides can act as carriers, clipping on drug payloads, radioactive atoms or oligonucleotides to reach tumours, muscle and brain. |
BioNTech Mainz, Germany | |
Develops mRNA vaccines and therapeutics, including individualized mRNA cancer immunotherapies, alongside other immunotherapy modalities. | Talk Thu Nov 5 16:00–16:30 Addressing Challenges in the Development and Quality Control of Individualized mRNA Products Why mRNA medicines made for one patient at a time are hard to quality-check, and how to show each new sequence is comparable. |
Cantoni Therapeutics Oss, Netherlands | |
Leiden University spinout developing small molecule NNMT inhibitors for obesity and its cardiometabolic complications. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TIDES Europe 2026 by
Organization type
Focus
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction